$78.26+0.33% 1DFinazon · prior-day close · Sep 4, 2026
Price · Chart
Our own end-of-day closes61 sessions
$90$7010 Jun4 Sep
The line runs $80.87 on 10 June through $78.26 on 4 September, on a scale from $70 to $90. Days the market did not trade hold the previous close, flat.
The chart above plots the price of GMED over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 61 sessions over that window: $80.87 on 10 June 2026 through $78.26 on 4 September 2026.
GMED has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 12 December 2025.
DateInsiderTypeSharesValue
12 Dec 2025Norwalk Leslie VSell4,000$355K
01 Dec 2025Kline KyleSenior Vice President, CFOSell18,542$1.67M
25 Nov 2025Huller KellySVP, GC, Corporate SecretarySell7,500$675K
12 Nov 2025Davidar David DSell25,000$2.15M
11 Nov 2025ZARRILLI STEPHEN TSell25,000$2.11M
10 Nov 2025RHOADS ANN DSell2,000$170K
07 Nov 2025RHOADS ANN DSell8,000$648K
15 Sep 2025RHOADS ANN DSell10,000$585K
Compensation mechanics
Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
DateInsiderTypeSharesValue
08 Dec 2025Paul David CExecutive ChairmanOption exercise34,375$877K
01 Dec 2025Kline KyleSenior Vice President, CFOOption exercise13,542$788K
25 Nov 2025Huller KellySVP, GC, Corporate SecretaryOption exercise7,500$195K
12 Nov 2025Davidar David DOption exercise25,000$638K
11 Nov 2025ZARRILLI STEPHEN TOption exercise25,000$1.10M
GMED reported financials
SEC EDGAR XBRL
GMED reported revenue of $2.9B for the fiscal year ended 31 Dec 2025. Net income over the same period was $537.9M.
FigureReportedPeriod
Revenue
$2.9B
31 Dec 2025 fiscal year
Net income
$537.9M
31 Dec 2025 fiscal year
Diluted EPS
$3.92
31 Dec 2025 fiscal year
Total assets
$5.5B
30 Jun 2026 at period end
Total equity
$4.8B
30 Jun 2026 at period end
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
GMED earnings
SEC EDGAR
DatePeriodEPSRevenue
30 Jun 2026Q2 2026$1.10$790M
31 Mar 2026Q1 2026$0.90$760M
31 Dec 2025FY 2025$3.92$2.94B
30 Sep 2025Q3 2025$0.88$769M
30 Jun 2025Q2 2025$1.49$745M
31 Mar 2025Q1 2025$0.54$598M
31 Dec 2024FY 2024$0.75$2.52B
30 Sep 2024Q3 2024$0.38$626M
Next report no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
8 of the 45 institutional funds we track reported a GMED position for the quarter ended 30 Jun 2026 — a combined $78.6M; the latest of those filings landed 02 Sep 2026.